AnangJBM. Levodopa-carbidopa-related rash in Parkinson's disease: a case series. Can J Neurol Sci, 2018; 45:588–589.
2.
SkorvamekM, BhatiaK. The skin and Parkinson's disease: review of clinical, diagnostic, and therapeutic issues. Mov Disord Clin Pract, 2017; 4:21–31.
3.
KardaunSH, SekulaP, Valeyrie-AllanoreL, et al., RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol, 2013; 169:1071–1080.
4.
BougeaA, SpantideasN, KatoulisA, et al.. Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach. Acta Neurol Belg, 2019; 119:325–336.
5.
Cansino-TorresMA, Sandoval-RodríguezV, Sáenz-FarretM, et al.. Allergy to carbidopa. Clin Neuropharmacol, 2018; 41:75–79.
6.
BarbaudA, ColletE, MilpiedB, et al.. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol, 2013; 168:555–562.
